5 results about "Epiandrosterone" patented technology

This invention discloses a method for preparing 7α,15α-dihydroxydehydroepiandrosterone (DHEA). The method comprises the following steps: DHEA is fed into a liquid culture medium containing *Colletotrichum lini* to convert the DHEA into 7α,15α-dihydroxydehydroepiandrosterone. The *Colletotrichum lini* liquid culture medium also contains cyclodextrin and its derivatives, and Tween. The conversion step includes: first, a low-temperature conversion, followed by a medium-temperature conversion; the low-temperature conversion conditions are: a conversion temperature of 15–20°C, preferably 16°C; the medium-temperature conversion conditions are: a conversion temperature of 28°C. Furthermore, by adding cyclodextrin and its derivatives and Tween, the feed amount of 7α,15α-dihydroxydehydroepiandrosterone prepared in this invention can be increased from 15 g / L to 30 g / L, and the relative conversion rate can reach 90%.

This invention proposes a method for preparing dehydroepiandrosterone (DHEA), comprising the following steps: S1, dissolving 4-androstenedione in acetic anhydride to obtain a first material, which is then pumped separately into an acetylation microchannel reactor with quaternized GO-phosphotungstic acid catalyst supported on the inner wall for reaction with acetyl chloride; S2, mixing triethyl orthoformate with anhydrous ethanol to obtain a second material, which is then pumped separately into a ketal microchannel reactor with niobium oxide / γ-CD-phosphotungstic acid catalyst supported on the inner wall of the ketal microchannel reactor; S3, dehydrating the effluent from step S2 and adjusting the pH to 7-8, then pumping separately into a reduction microchannel reactor with an ethanol solution containing sodium borohydride for reduction reaction; S4, adding hydrochloric acid to the effluent from step S3 and adjusting the pH to 2-3 to obtain a hydrolysate; evaporating the solvent from the hydrolysate, filtering and drying to obtain DHEA. The supported heteropolyacid composite membrane used in this invention exhibits high catalytic efficiency, high yield, and excellent quality.

The present application relates to a kind of P450 enzyme mutant and its application in the preparation of trihydroxy androstene ketone by catalyzing DHEA hydroxylation.The present application provides four kinds of cytochrome P450 enzyme mutants, which are based on wild-type P450 enzyme, the alanine at position 112 is mutated to tyrosine, histidine, lysine and serine respectively by site-directed mutagenesis, which significantly improves the catalytic efficiency, can efficiently catalyze dehydroepiandrosterone (DHEA) to prepare product trihydroxy androstene ketone by two-step hydroxylation reaction.Compared with wild-type cytochrome P450 enzyme, these mutants show excellent catalytic performance, and have important industrial application value in the field of steroid drug synthesis.

The application discloses a nucleic acid aptamer specifically combined with dehydroepiandrosterone, a kit and application, and comprises a nucleotide sequence shown in SEQ ID No. 1; or a nucleotide sequence with high homology with the nucleotide sequence shown in SEQ ID No. 1 and capable of being specifically combined with dehydroepiandrosterone; or a nucleotide sequence derived from the nucleotide sequence shown in SEQ ID No. 1 and capable of being specifically combined with dehydroepiandrosterone; wherein the primer of dehydroepiandrosterone comprises lib1S1, Lib1A2 and Lib1S1-CS-biotin. The nucleic acid aptamer with high affinity and high specificity is screened, has strong specificity and sensitivity, is a chemical synthetic material, has low use cost and does not have the problem of batch difference in the detection process, and the use of antibody material in the detection process is avoided, so that the detection cost is reduced.